Skip to main content
. 2017 Mar;29(3):188–197. doi: 10.1016/j.clon.2016.10.005

Table 3.

Chemotherapy regimens

UK audit
(n = 242)
Chemotherapy regimen
 MMC 5-FU 156 (64.5%)
 MMC capecitabine 68 (28.1%)
 Cisplatin/5-FU 3 (1.2%)
 MMC alone 1 (0.4%)
 5-FU alone 1 (0.4%)
 Capecitabine alone 2 (0.8%)
 Cisplatin/Etoposide 2 (0.8%)
 No chemotherapy 8 (3.3%)
 Cisplatin alone 1 (0.4%)

MMC, mitomycin; 5-FU, 5-fluorouracil.